Eduardo Caio Torres-Santos

List of Publications by Year
in descending order

46 papers	1,454 citations	331670 21 h-index	330143 37 g-index
46 all docs	46 docs citations	46 times ranked	2279 citing authors

#	Article	IF	Citations
1	Simvastatin Resistance of Leishmania amazonensis Induces Sterol Remodeling and Cross-Resistance to Sterol Pathway and Serine Protease Inhibitors. Microorganisms, 2022, 10, 398.	3.6	2
2	Host cholesterol influences the activity of sterol biosynthesis inhibitors in Leishmania amazonensis. Memorias Do Instituto Oswaldo Cruz, 2022, 117, e220407.	1.6	3
3	Oral and Intragastric: New Routes of Infection by Leishmania braziliensis and Leishmania infantum?. Pathogens, 2022, 11, 688.	2.8	4
4	Energy metabolism as a target for cyclobenzaprine: A drug candidate against Visceral Leishmaniasis. Bioorganic Chemistry, 2022, 127, 106009.	4.1	0
5	Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis. Frontiers in Pharmacology, 2021, 12, 636265.	3.5	4
6	Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	10
7	Naphthoquinones and Derivatives for Chemotherapy: Perspectives and Limitations of their Anti-trypanosomatids Activities. Current Pharmaceutical Design, 2021, 27, 1807-1824.	1.9	9
8	Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity. ACS Medicinal Chemistry Letters, 2021, 12, 1405-1412.	2.8	9
9	Sterol profile of Neobenedenia melleni, a marine ectoparasite fish. Molecular and Biochemical Parasitology, 2021, 246, 111414.	1.1	0
10	Miltefosine-Lopinavir Combination Therapy Against Leishmania infantum Infection: In vitro and in vivo Approaches. Frontiers in Cellular and Infection Microbiology, 2019, 9, 229.	3.9	19
11	Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 353.	3.9	18
12	Evaluation of Novel Chalcone-Thiosemicarbazones Derivatives as Potential Anti-Leishmania amazonensis Agents and Its HSA Binding Studies. Biomolecules, 2019, 9, 643.	4.0	15
13	Original antileishmanial hits: Variations around amidoximes. European Journal of Medicinal Chemistry, 2018, 148, 154-164.	5.5	3
14	Anti-Mycobacterium tuberculosis activity of essential oil and 6,7-dehydroroyleanone isolated from leaves of Tetradenia riparia (Hochst.) Codd (Lamiaceae). Phytomedicine, 2018, 47, 34-39.	5.3	32
15	<i>In Vitro</i> and <i>In Vivo</i> Studies of the Trypanocidal Effect of Novel Quinolines. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
16	Second-generation pterocarpanquinones: synthesis and antileishmanial activity. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2018, 24, 35.	1.4	6
17	Leishmanicidal Activity of Withanolides from Aureliana Fasciculata var. Fasciculata. Molecules, 2018, 23, 3160.	3.8	11
18	Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism of<i>Leishmania amazonensis</i>promastigotes. Parasitology, 2018, 145, 1304-1310.	1.5	13

#	Article	IF	Citations
19	Leishmaniasis treatment update of possibilities for drug repurposing. Frontiers in Bioscience - Landmark, 2018, 23, 967-996.	3.0	53
20	Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice. PLoS Neglected Tropical Diseases, 2017, 11, e0005281.	3.0	19
21	Suzuki-Miyaura Coupling between 3-Iodolawsone and Arylboronic Acids. Synthesis of Lapachol Analogues with Antineoplastic and Antileishmanial Activities. Journal of the Brazilian Chemical Society, 2016, , .	0.6	2
22	Evaluation of Chemical Composition and Antileishmanial and Antituberculosis Activities of Essential Oils of Piper Species. Molecules, 2016, 21, 1698.	3.8	46
23	Preclinical Studies Evaluating Subacute Toxicity and Therapeutic Efficacy of LQB-118 in Experimental Visceral Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2016, 60, 3794-3801.	3.2	22
24	Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, <i>In Vitro</i> Synergy with Azoles, and Efficacy in Experimental Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2016, 60, 6844-6852.	3.2	21
25	Imipramine alters the sterol profile in Leishmania amazonensis and increases its sensitivity to miconazole. Parasites and Vectors, 2016, 9, 183.	2.5	25
26	Novel 3,4-methylenedioxyde-6-X-benzaldehyde-thiosemicarbazones: Synthesis and antileishmanial effects against Leishmania amazonensis. European Journal of Medicinal Chemistry, 2015, 103, 409-417.	5.5	37
27	Oral effectiveness of PMIC4, a novel hydroxyethylpiperazine analogue, in Leishmania amazonensis. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 210-213.	3.4	2
28	Effectiveness of Novel 5â€(5â€aminoâ€1â€arylâ€1<i>H</i>â€pyrazolâ€4â€yl)â€1<i>H</i>â€tetrazole Derivatives Against Promastigotes and Amastigotes of <i>Leishmania amazonensis</i>. Chemical Biology and Drug Design, 2014, 83, 272-277.	3.2	9
29	The New Pyrazolyltetrazole Derivative MSN20 Is Effective via Oral Delivery against Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6290-6293.	3.2	6
30	Pterocarpanquinone LQB-118 Induces Apoptosis in Leishmania (Viannia) braziliensis and Controls Lesions in Infected Hamsters. PLoS ONE, 2014, 9, e109672.	2.5	20
31	Antileishmanial activity of amides from Piper amalago and synthetic analogs. Revista Brasileira De Farmacognosia, 2013, 23, 447-454.	1.4	27
32	LQB-118, an orally active pterocarpanquinone, induces selective oxidative stress and apoptosis in Leishmania amazonensis. Journal of Antimicrobial Chemotherapy, 2013, 68, 789-799.	3.0	57
33	The stepwise selection for ketoconazole resistance induces upregulation of C14-demethylase (CYP51) in Leishmania amazonensis. Memorias Do Instituto Oswaldo Cruz, 2012, 107, 416-419.	1.6	11
34	HPLC Analysis of Supercritical Carbon Dioxide and Compressed Propane Extracts from Piper amalago L. with Antileishmanial Activity. Molecules, 2012, 17, 15-33.	3.8	33
35	LDL uptake by Leishmania amazonensis: Involvement of membrane lipid microdomains. Experimental Parasitology, 2012, 130, 330-340.	1.2	45
36	The pharmacological inhibition of sterol biosynthesis in Leishmania is counteracted by enhancement of LDL endocytosis. Acta Tropica, 2011, 119, 194-198.	2.0	33

#	Article	IF	Citations
37	Pterocarpanquinones, aza-pterocarpanquinone and derivatives: Synthesis, antineoplasic activity on human malignant cell lines and antileishmanial activity on Leishmania amazonensis. Bioorganic and Medicinal Chemistry, 2011, 19, 6885-6891.	3.0	42
38	Effectiveness of the local or oral delivery of the novel naphthopterocarpanquinone LQB-118 against cutaneous leishmaniasis. Journal of Antimicrobial Chemotherapy, 2011, 66, 1555-1559.	3.0	35
39	Modulation of P2X7 purinergic receptor in macrophages by Leishmania amazonensis and its role in parasite elimination. Microbes and Infection, 2009, 11, 842-849.	1.9	75
40	Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone. Journal of Antimicrobial Chemotherapy, 2009, 63, 469-472.	3.0	39
41	Antitumoral, antileishmanial and antimalarial activity of pentacyclic 1,4-naphthoquinone derivatives. Journal of the Brazilian Chemical Society, 2009, 20, 176-182.	0.6	46
42	Synthesis of chalcone analogues with increased antileishmanial activity. Bioorganic and Medicinal Chemistry, 2006, 14, 1538-1545.	3.0	201
43	Antileishmanial activity of isolated triterpenoids from Pourouma guianensis. Phytomedicine, 2004, 11, 114-120.	5.3	98
44	Toxicological analysis and effectiveness of oralKalanchoe pinnata on a human case of cutaneous leishmaniasis. Phytotherapy Research, 2003, 17, 801-803.	5.8	35
45	Improvement of In Vitro and In Vivo Antileishmanial Activities of 2â€²,6â€²-Dihydroxy-4â€²-Methoxychalcone by Entrapment in Poly(<scp>d,l</scp> -Lactide) Nanoparticles. Antimicrobial Agents and Chemotherapy, 1999, 43, 1776-1778.	3.2	66
46	Selective Effect of 2â€²,6â€²-Dihydroxy-4â€²-Methoxychalcone Isolated from<i>Piper aduncum</i>on<i>Leishmania amazonensis</i>. Antimicrobial Agents and Chemotherapy, 1999, 43, 1234-1241.	3.2	172